GlassScriptPhysician profile
Roger M Gibson
NPI 1083681043
$2,038.83
in general payments reported to CMS, 2019-2025
21 companies · $878 in 2025
The $878 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.61 · 2022: $46.85 · 2023: $245 · 2024: $849 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.65 | 2023-2025 | |
| Lilly USA, LLC | $353.89 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $194.36 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $169.44 | 2024-2025 | Repatha, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.21 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $63.64 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $63.15 | 2024-2025 | Xyosted |
| Corium, LLC | $62.02 | 2024-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $61.13 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $59.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.97 | 2024-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.29 | 2023-2025 | Jardiance |
| Noven Therapeutics, LLC | $40.30 | 2024 | Xelstrym |
| Ardelyx, INC. | $38.42 | 2024 | Ibsrela |
| Ibsa Pharma INC. | $33.61 | 2025 | Licart, Flector, Tirosint |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $25.92 | 2024 | Cequr Simplicity |
| Abbott Laboratories | $19.59 | 2022 | |
| Dynavax Technologies Corporation | $17.20 | 2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
| Tolmar, INC. | $15.02 | 2025 | Jatenzo |
| Supernus Pharmaceuticals, INC. | $14.09 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.